{"nctId":"NCT00770653","briefTitle":"Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.","startDateStruct":{"date":"2007-04"},"conditions":["Diabetes Mellitus","Dyslipidemias"],"count":305,"armGroups":[{"label":"Pioglitazone 15 mg and Metformin 850 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Pioglitazone and Metformin"]},{"label":"Glimepiride 2 mg and Metformin 850 mg BID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glimepiride and Metformin"]}],"interventions":[{"name":"Pioglitazone and Metformin","otherNames":["ACTOS®","AD-4833","OPIMET"]},{"name":"Glimepiride and Metformin","otherNames":["Amaryl","Glista"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes according to the American Diabetes Association Criteria.\n* Treatment with individual maximal tolerated dose of metformin (850 - 2000 mg) as monotherapy within the last 12 weeks.\n* Glycosylated Hemoglobin greater than or equal to 6.5% and less than or equal to 9%.\n* Dyslipidemia defined as high-density lipoprotein cholesterol less than or equal to 1.03 mmol/l (40 mg/dL) and/or triglycerides greater than or equal to 1.7 mmol/l (150 mg/dL).\n* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus.\n* Insulin-dependent type 2 diabetes mellitus.\n* Treatment or history of treatment with any insulin formulation other than emergency for more than 2 weeks.\n* Treatment with other oral antidiabetic drugs in addition to metformin within the last 12 weeks.\n* Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.\n* Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:\n\n  * Heparin (and heparin-like drugs)\n  * coumarin\n  * phenprocoumon\n  * hirudin\n  * Protein C\n  * Fondaparinux\n  * antithrombin III\n  * Peroxisome Proliferation Activating Receptor (gamma) agonists\n  * Treatment within the last 12 weeks with:\n\n    * fibrates\n    * gemfibrozil\n    * niacin\n    * months\n    * Rifampicin\n  * Changes in dosage of any statin treatment to lower low-density lipoprotein within 2 weeks before study entry and during study participation interval.\n  * Changes in dosage of any anticoagulant treatment with acetyl salicylic acid and/or clopidogrel within 2 weeks before study entry and during study participation interval.\n  * Start of statin and/or anticoagulant treatment during study participation interval.\n* History of severe or multiple allergies and/ or acute severe infections.\n* Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.\n* Progressive fatal disease.\n* Any elective surgery during study participation.\n* History of drug or alcohol abuse within the last 5 years.\n* A history of significant cardiovascular (New York Heart Association stage I - IV), respiratory, gastrointestinal, hepatic (alanine aminotransferase and/or aspartate aminotransferase greater than 2.5 times the upper limit of the normal reference range), renal (serum creatinine greater than 1.2 mg/dL in women and greater than 1.5 mg/dL in men, glomerular filtration rate less than 60 ml/min as estimated by the Cockroft-Gault formula), neurological, psychiatric and/or hematological disease as judged by the investigator, history of macular edema.\n* Blood donation within the last 30 days.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.","description":"The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"9.7"},{"groupId":"OG001","value":"-0.3","spread":"11.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in High-Density Lipoprotein Cholesterol.","description":"The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"9.6"},{"groupId":"OG001","value":"-0.4","spread":"11.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.","description":"The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.8"},{"groupId":"OG001","value":"0.3","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Triglycerides.","description":"The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.9","spread":"113.8"},{"groupId":"OG001","value":"-16.7","spread":"121.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Low-Density Lipoprotein Subfractions.","description":"The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"17.5"},{"groupId":"OG001","value":"6.1","spread":"26.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Low-Density Lipoprotein Cholesterol.","description":"The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"34.7"},{"groupId":"OG001","value":"11.2","spread":"25.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycosylated Hemoglobin.","description":"The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"0.87"},{"groupId":"OG001","value":"-0.95","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Intact Proinsulin.","description":"The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.18","spread":"11.89"},{"groupId":"OG001","value":"-0.11","spread":"9.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Glucose.","description":"The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.6","spread":"38.6"},{"groupId":"OG001","value":"-21.1","spread":"40.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Adiponectin.","description":"The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.79","spread":"6.38"},{"groupId":"OG001","value":"0.72","spread":"2.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in High Sensitivity C-reactive Protein (Original).","description":"The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"8.98"},{"groupId":"OG001","value":"-0.04","spread":"9.53"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).","description":"The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.87","spread":"1.88"},{"groupId":"OG001","value":"0.00","spread":"1.83"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Systolic Blood Pressure.","description":"The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"14.8"},{"groupId":"OG001","value":"0.5","spread":"13.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Diastolic Blood Pressure.","description":"The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"8.7"},{"groupId":"OG001","value":"-0.1","spread":"8.8"}]}]}]},{"type":"SECONDARY","title":"Intake of Study Medication Greater Than 80% and Less Than 120%.","description":"The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"137","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Nitrotyrosine.","description":"The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"93.2"},{"groupId":"OG001","value":"32.5","spread":"147.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Soluble CD40 Ligand.","description":"The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.7","spread":"248.6"},{"groupId":"OG001","value":"102.4","spread":"379.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Matrix Metallo Proteinase-9.","description":"The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":"228.3"},{"groupId":"OG001","value":"51.6","spread":"216.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Soluble Intracellular Adhesion Molecule.","description":"The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.0","spread":"46.9"},{"groupId":"OG001","value":"-3.2","spread":"50.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Soluble Vascular Cell Adhesion Molecule.","description":"The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"160.6"},{"groupId":"OG001","value":"3.3","spread":"115.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Thromboxane B2.","description":"The change between the value of Thromboxane B2 collected at week 24 or final visit and Thromboxane B2 collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-216.4","spread":"842.9"},{"groupId":"OG001","value":"527.8","spread":"1190.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Platelet Function.","description":"The change between the value of Platelet Function by PFA 100 collected at week 24 or final visit and Platelet Function by PFA 100 collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.3","spread":"44.3"},{"groupId":"OG001","value":"-1.0","spread":"102.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in E-Selectin.","description":"The change between the value of E-Selectin collected at week 24 or final visit and E-Selectin collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"4.8"},{"groupId":"OG001","value":"-0.5","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Von-Willebrand Factor.","description":"The change between the value of Von-Willebrand Factor collected at week 24 or final visit and Von-Willebrand Factor collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.5","spread":"32.0"},{"groupId":"OG001","value":"1.4","spread":"33.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Erythrocyte Deformability (0.30%).","description":"The change between the 0.30 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"2.1"},{"groupId":"OG001","value":"-0.4","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Erythrocyte Deformability (0.60%)","description":"The change between the 0.60 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.3"},{"groupId":"OG001","value":"-0.5","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Erythrocyte Deformability (1.20).","description":"The change between the 1.20 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"2.2"},{"groupId":"OG001","value":"-1.1","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Erythrocyte Deformability (3.00).","description":"The change between the 3.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"2.8"},{"groupId":"OG001","value":"-.15","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Erythrocyte Deformability (6.00).","description":"The change between the 6.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"2.9"},{"groupId":"OG001","value":"-1.4","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Erythrocyte Deformability (12.00).","description":"The change between the 12.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"2.8"},{"groupId":"OG001","value":"-1.3","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Erythrocyte Deformability (30.00).","description":"The change between the 30.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"2.6"},{"groupId":"OG001","value":"-1.3","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Erythrocyte Deformability (60.00).","description":"The change between the 60.00 percent value of Erythrocyte (Red Blood Cell) Deformability collected at week 24 or final visit and Erythrocyte Deformability collected at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"2.6"},{"groupId":"OG001","value":"-1.3","spread":"3.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":153},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Oedema peripheral","Arthralgia"]}}}